Zoledronic Acid As a Therapeutic For Dry Age-Related Macular Degeneration and Stargardt Disease

The invention is a therapeutic intended to prevent the onset and progression of age-related macular degeneration (MD) as well as Stargardt disease-related vision loss.

UCSF/University of Wisconsin researchers have identified that abnormal activation of acid sphingomyelinase (ASM) in the retinal pigment epithelium (RPE) serves as a pathological trigger in dry age-related MD and Stargardt’s disease. Activation of ASM results in increased ceramide, which makes the RPE (the tissue that is responsible for nourishment and support of light-sensing photoreceptors) susceptible to damage. The RPE is the primary site of damage for both Stargardt inherited and age-related MD.



Contact Information

Name: Lindsay Sanford

Email: Lindsay.Sanford@ucsf.edu